SG11201506430XA - Metadichol r liquid and gel nanoparticle formulations - Google Patents

Metadichol r liquid and gel nanoparticle formulations

Info

Publication number
SG11201506430XA
SG11201506430XA SG11201506430XA SG11201506430XA SG11201506430XA SG 11201506430X A SG11201506430X A SG 11201506430XA SG 11201506430X A SG11201506430X A SG 11201506430XA SG 11201506430X A SG11201506430X A SG 11201506430XA SG 11201506430X A SG11201506430X A SG 11201506430XA
Authority
SG
Singapore
Prior art keywords
metadichol
liquid
nanoparticle formulations
gel nanoparticle
gel
Prior art date
Application number
SG11201506430XA
Other languages
English (en)
Inventor
Palayakotai R Raghavan
Original Assignee
Nanorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanorx Inc filed Critical Nanorx Inc
Publication of SG11201506430XA publication Critical patent/SG11201506430XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
SG11201506430XA 2013-03-15 2014-03-11 Metadichol r liquid and gel nanoparticle formulations SG11201506430XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794490P 2013-03-15 2013-03-15
PCT/US2014/023777 WO2014150609A1 (en) 2013-03-15 2014-03-11 Metadichol r liquid and gel nanoparticle formulations

Publications (1)

Publication Number Publication Date
SG11201506430XA true SG11201506430XA (en) 2015-09-29

Family

ID=51530033

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506430XA SG11201506430XA (en) 2013-03-15 2014-03-11 Metadichol r liquid and gel nanoparticle formulations

Country Status (15)

Country Link
US (1) US9006292B2 (enrdf_load_stackoverflow)
EP (1) EP2968209B1 (enrdf_load_stackoverflow)
JP (2) JP5996146B2 (enrdf_load_stackoverflow)
KR (1) KR101700949B1 (enrdf_load_stackoverflow)
CN (1) CN105188687B (enrdf_load_stackoverflow)
AU (1) AU2014235779B2 (enrdf_load_stackoverflow)
BR (1) BR112015011379B1 (enrdf_load_stackoverflow)
CA (1) CA2894370C (enrdf_load_stackoverflow)
DK (1) DK2968209T3 (enrdf_load_stackoverflow)
HK (1) HK1212247A1 (enrdf_load_stackoverflow)
MX (1) MX359686B (enrdf_load_stackoverflow)
RU (2) RU2631600C2 (enrdf_load_stackoverflow)
SG (1) SG11201506430XA (enrdf_load_stackoverflow)
WO (1) WO2014150609A1 (enrdf_load_stackoverflow)
ZA (1) ZA201505436B (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4435105A3 (en) 2015-09-29 2025-05-14 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
CN114746080B (zh) * 2019-09-30 2024-11-22 托尔玛国际有限公司 用于作为活性药物成分的肽的延长递送的液体聚合物组合物和系统
US11554087B2 (en) 2020-11-05 2023-01-17 The Gillette Company Llc Shaving aid comprising an antioxidant
CN114699537B (zh) * 2022-03-07 2024-06-21 西安交通大学医学院第一附属医院 一种改善缺氧增敏pd-1抗体疗效的ros响应抗癌药物
WO2024105417A1 (en) * 2022-11-18 2024-05-23 Phytoceutical Limited Biofilm treatment
CN118011012B (zh) * 2024-02-19 2025-01-21 中国科学院昆明动物研究所 LL-37-ApoB-100生物标志物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670471A (en) * 1981-11-03 1987-06-02 Clark Lealand L Treatment for inflammatory skin disease
US20090191288A1 (en) 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US20030198616A1 (en) * 2002-04-23 2003-10-23 Combe Incorporated Moisturizing skin gel and method
AU2003241477A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
ITMI20031313A1 (it) * 2003-06-27 2004-12-28 Indena Spa Associazioni di agenti vasoprotettori e formulazioni che li contengono.
US7217546B1 (en) * 2003-07-01 2007-05-15 Sami Labs Ltd Commercially viable process for high purity of fatty alcohol C24 to C36 and its cosmetic application for skin hair and nails
US20050074443A1 (en) 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
EP2097074A4 (en) * 2006-12-04 2013-05-01 Glaxosmithkline Llc TOPICAL PHARMACEUTICAL COMPOSITION
JP5711671B2 (ja) * 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドNanorx,Inc. ポリコサノールナノ粒子
CN102686205A (zh) * 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
WO2012027159A1 (en) * 2010-08-23 2012-03-01 NanoRx, Inc. Policosanol nanoparticles
US20130045179A1 (en) * 2011-08-15 2013-02-21 Mihai Ciustea Combination therapy and methods for treatment and prevention of hyperproliferative diseases

Also Published As

Publication number Publication date
JP6346918B2 (ja) 2018-06-20
HK1212247A1 (en) 2016-06-10
JP5996146B2 (ja) 2016-09-21
ZA201505436B (en) 2016-07-27
AU2014235779B2 (en) 2015-11-26
US9006292B2 (en) 2015-04-14
KR20150127575A (ko) 2015-11-17
MX359686B (es) 2018-10-05
EP2968209A1 (en) 2016-01-20
DK2968209T3 (da) 2021-01-04
CN105188687B (zh) 2018-05-01
KR101700949B1 (ko) 2017-01-31
CN105188687A (zh) 2015-12-23
CA2894370C (en) 2016-01-12
MX2015008676A (es) 2016-04-25
JP2016512827A (ja) 2016-05-09
RU2631600C2 (ru) 2017-09-25
RU2017116682A3 (enrdf_load_stackoverflow) 2020-06-03
RU2736752C2 (ru) 2020-11-19
EP2968209B1 (en) 2020-12-16
BR112015011379B1 (pt) 2022-10-11
AU2014235779A1 (en) 2015-09-03
BR112015011379A2 (enrdf_load_stackoverflow) 2017-08-22
US20140275285A1 (en) 2014-09-18
EP2968209A4 (en) 2016-11-02
CA2894370A1 (en) 2014-09-25
RU2015143270A (ru) 2017-04-27
RU2017116682A (ru) 2018-10-23
WO2014150609A1 (en) 2014-09-25
JP2017008057A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
GB2535911B (en) Strigolactone formulations and uses thereof
IL245733A0 (en) aplnr modulators and their uses
IL286759A (en) Therapeutic methods and preparations
IL246221B (en) Endazoles and their uses
EP2964022A4 (en) ANALGIC COMBINATION AND USE
GB201317286D0 (en) Composition and Use
RS58758B9 (sr) Vatrostalna smesa i njena upotreba
SG11201508167PA (en) Therapeutic compositions and uses thereof
HRP20170874T1 (hr) Formulacija kontrastnog medija i odgovarajući postupak dobivanja
ZA201505436B (en) Metadichol r liquid and gel nanoparticle formulations
TWI562776B (en) Pharmaceutical composition and uses thereof
EP3015525A4 (en) HYDROPHILIC THICKENER AND COSMETIC COMPOSITION THEREWITH
GB2532663B (en) Liquid mouthwash
EP2983472A4 (en) IONIC LIQUIDS AND THEIR USES
GB201318151D0 (en) Composition and device
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
IL240177A (en) Chromium-6-Iloxy-cycloalkanes are conserved and used as drugs
IL240768A0 (en) Nanoparticulate and macroparticulate formulations
EP3055286A4 (en) 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use
EP3071207A4 (en) Libido-enhancing therapeutic and use
AU2013901834A0 (en) Formulations and Therapeutic Uses Thereof
TWM475607U (en) Shampooing eyeshade
AU2013903458A0 (en) Macromolecules and their use
GB201320958D0 (en) Improvements in and relating to medical devices
GB201319255D0 (en) Therapeutic compositions and methods